Author: Mazalovska, Milena; Kouokam, J. Calvin
Title: Lectins as Promising Therapeutics for the Prevention and Treatment of HIV and Other Potential Coinfections Document date: 2018_5_8
ID: 0spmy8vn_33
Snippet: Coronaviruses constitute an important class of human and animal pathogens, and some have been assessed for their susceptibility to lectins. Interestingly, GRFT also prevents SARS coronavirus (SARS-CoV) infection in vitro and in vivo, through specific binding to its spike glycoprotein, and shows activity against multiple other coronaviruses pathogenic to humans, other mammals, and birds; in mice, these inhibitory effects were accompanied with a sp.....
Document: Coronaviruses constitute an important class of human and animal pathogens, and some have been assessed for their susceptibility to lectins. Interestingly, GRFT also prevents SARS coronavirus (SARS-CoV) infection in vitro and in vivo, through specific binding to its spike glycoprotein, and shows activity against multiple other coronaviruses pathogenic to humans, other mammals, and birds; in mice, these inhibitory effects were accompanied with a specific inhibition of deleterious host immune reactions in response to SARS [85] . The Middle East respiratory syndrome coronavirus (MERS-CoV), another highly pathogenic human coronavirus, is inhibited at the entry level by GRFT to prevent infection in vitro [86] . In addition, Hippeastrum hybrid agglutinin (HHA), GNA, Cymbidium agglutinin (CA), and Urtica dioica agglutinin (UDA) demonstrate antiviral activities against coronaviruses in vitro and/or in vivo [67] . In an impressive screening of 33 plant lectins, remarkable antiviral effects on both SARS-CoV and feline infectious peritonitis virus (FIPV) with EC50 values at low g/ml levels were observed, with strongest activities found predominantly among mannosebinding lectins [66] . Based on these data, lectins should be included in antiviral strategies to fight SARS coronavirus infections [87] .
Search related documents:
Co phrase search for related documents- SARS coronavirus infection and spike glycoprotein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32
- SARS CoV infection and specific binding: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- SARS CoV infection and specific inhibition: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- SARS CoV infection and spike glycoprotein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- SARS CoV infection and spike glycoprotein specific binding: 1, 2, 3
- SARS CoV infection and strong activity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
- SARS CoV infection and vivo vitro SARS CoV infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
- SARS response and specific binding: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35
- SARS response and specific inhibition: 1, 2, 3, 4
- SARS response and spike glycoprotein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55
- SARS response and spike glycoprotein specific binding: 1, 2
- SARS response and strong activity: 1, 2, 3, 4
- SARS response and vivo vitro SARS CoV infection: 1
- specific binding and spike glycoprotein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- specific binding and spike glycoprotein specific binding: 1, 2, 3, 4, 5, 6
- specific binding and strong activity: 1
- specific inhibition and spike glycoprotein: 1, 2, 3
- spike glycoprotein and strong activity: 1, 2, 3, 4, 5, 6, 7, 8, 9
- spike glycoprotein and vivo vitro SARS CoV infection: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date